Groundbreaking software program by Lucida Scientific, Pi, demonstrates a professional degree of overall performance and top-notch promise of enhancing accuracy, cost, and time required in prostate most cancer diagnosis

• Prostate most cancers is the most not unusual cancer in men with 375,000 annual deaths

• Pi software program improves the 12% “pass over price” of MRI in prostate most cancers analysis, helping ensure patients get the remedy they need

• The software program also can reduce the 55% of sufferers without sizable most cancers who’re referred for costly, painful, and potentially avoidable biopsy

• With an incorporated, computerized workflow and hazard rankings, the software accelerates analysis, supporting hospitals in tackling resourcing demanding situations and waiting instances while giving patients an excellent viable outcome.

CAMBRIDGE, United Kingdom (23 Oct 2023) – Lucida Scientific Ltd, a Cambridge-based start-up company dedicated to improving cancer prognosis, has acquired elegance IIb CE certification for its AI-based prostate cancer detection software program, Prostate Intelligence (Pi). constructed in partnership with leading clinicians and UK NHS hospitals, the CE mark manner the software can now gain patients across the United Kingdom and European healthcare systems.

Even as MRI is the favored imaging technique to assess several cancers, consisting of prostate cancer and metastatic ailment, inside the UK alone, radiologist numbers are forecasted to reach a shortfall of 40% using 2027, indicating an urgent want for a streamlined, simplified, and accurate method for cancer analysis.

A key scientific take a look at confirmed that radiologists can omit 12% of giant prostate cancers through the usage of MRI, and refer 55% of people without substantial most cancers for a painful and pricey biopsy. Information provided at the ECU Society for Urogenital Radiology (ESUR) in September 2023 indicated that Pi may want to help cut undetected cancers to 6% at the same time as additionally lowering avoidable biopsies to forty-three.

Using AI, Pi analyses the MRI and is completely integrated into the radiologist’s workflow, focused on key issues of variability, radiologist time, and diagnostic accuracy in prostate cancer. Particularly, Pi is meant to be utilized by radiologists to assess and record prostate MRI research, with the aid of automatically producing 3D segmentations, volumes, and threat ratings. Its outputs can be used to keep radiologists’ time and assist biopsy and remedy choices.

Because the most common cancer in guys, each year, prostate cancer gains 1.4 million diagnoses and claims 375,000 lives. inside the US alone, 288,000 are identified, and 35,000 die. there may be a super want and ability to improve its prognosis and treatment, which became shown by recent facts from Prostate Most cancers UK that highlighted stunning variability throughout the United Kingdom. 35% of men in Scotland with prostate cancer are recognized overdue at level 4, which results in debilitating treatment and less than 50% surviving five years. This compares with 12.five% identified at stage four in London. earlier detection can help lessen the prices of superior and metastatic disorders and in turn substantially enhance sufferers’ enjoyment, results, and life expectancy.

“We desperately want to reduce waiting times, locate most cancers early, and provide patients and clinicians with all of the records needed for maximum treatment,” explained Co-Founder and chief scientific Officer Professor Evis Sala, Chair of Radiology at the Università Cattolica del Sacro Cuore and Director of the superior Radiology Centre on the Policlinico Universitario A. Gemelli, IRCCS. “With this CE mark, the results of our investment in AI and clinical research over the last 4 years can now be used by doctors to provide the exceptional feasible analysis for guys with suspected prostate most cancers.”

“This CE certification establishes Pi as the leading platform to aid prostate most cancers analysis with MRI, from screening patients at increased threat to biopsy, analysis and remedy planning,” maintains Dr. Antony Rix, CEO and Co-Founder. “because the most effective AI solution for prostate MRI that integrates routinely with radiologists’ workflows and that has exceptional accuracy in actual-world validation, Pi has vast capacity to improve sufferers’ consequences and decrease prices and ready lists in health structures just like the NHS.”

Lucida Scientific will reveal Pi at the Radiological Society of North America (RSNA) 2023 Annual meeting from 26-29 November, in which the outcomes of the latest external validation of the software program will be offered in clinical consultation S1-SSGU01 through Dr. Francesco Giganti, Associate Professor of Radiology at college university London.

The agency plans to make Pi commercially to be had within the United Kingdom and ECU in Q1, 2024. Pi isn’t always on the market within the US.

About Lucida clinical

Lucida Scientific develops AI-primarily based generation to help clinicians locate cancer more appropriately, diagnose and deal with it extra efficaciously, and save time. A start-up business from the University of Cambridge, Lucida Medical turned based in 2019 by using Dr. Antony Rix, a professional in scientific gadgets, gadget studying, and AI, and Prof. Evis Sala, who at the time became a Professor of Oncological Imaging on the college of Cambridge & Addenbrooke’s clinic, and who is now Chair of Radiology at the Università Cattolica del Sacro Cuore and Director of the superior Radiology Centre at the Policlinico Universitario A. Gemelli, IRCCS in Rome. Prostate Intelligence (Pi) is meant for use to help the analysis of prostate cancer and is the organization’s first product to complete regulatory approvals.

Lucida Clinical is backed with the aid of traders along with XTX Ventures, Prostate most cancers research, and leading radiologists and urologists. Following a successful collaboration with GE HealthCare in 2021, the agency is now piloting the software program in the United Kingdom, Germany, and Italy, and building partnerships with hospitals and main vendors to make Pi available throughout Europe.